Leap Therapeutics, Inc. (LPTX) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 3 Buy, 1 Hold.
The consensus price target is $5.50, representing an upside of 614.7% from the current price $0.77.
Analysts estimate Earnings Per Share (EPS) of $-1.88 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.81 vs est $-1.88 (beat +3.5%). 2025: actual $0.07 vs est $-1.11 (beat +106.6%). Analyst accuracy: 0%.
LPTX Stock — 12-Month Price Forecast
$5.50
▲ +614.66% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Leap Therapeutics, Inc., the price target is $5.50.
The average price target represents a +614.66% change from the last price of $0.77.
LPTX Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Leap Therapeutics, Inc. in the past 3 months
EPS Estimates — LPTX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.81
vs Est –$1.88
▲ 3.6% off
2025
Actual $0.07
vs Est –$1.11
▲ 1,622.6% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — LPTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
